博雅生物(300294.SZ)：获得破伤风人免疫球蛋白《药品注册证书》

Core Viewpoint - The company, Boya Bio-Pharmaceutical (300294.SZ), has received the Drug Registration Certificate for Tetanus Human Immunoglobulin from the National Medical Products Administration, which enhances its product pipeline and boosts research enthusiasm [1]. Group 1 - The company has invested a total of 9.75 million yuan in the research and development of Tetanus Human Immunoglobulin [1]. - The acquisition of the Drug Registration Certificate is expected to enrich the company's product offerings [1]. - This development is likely to improve the company's research and development motivation [1].